Continuous infusion (CI), or protracted venous infusion (PVI), is used as an alternative to bolus infusion in a variety of circumstances.

Numerous studies have been conducted for specific conditions, therapies and agents. In general, these studies conclude that CI offers patients benefits which may include improved clinical outcomes, reduced toxicity and side effects, greater freedom and mobility, and improvements in average daily living (ADL) function.  Practices generally observe benefits which include improved clinical outcomes, reduced toxicity and side effects resulting in improved adherence to therapy, and reimbursement for appropriate clinical services related to the administration of continuous infusion.